How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about belantamab mafodotin

Conditional marketing authorisation indication

2.1 Belantamab mafodotin (Blenrep, GlaxoSmithKline) is indicated 'as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for belantamab mafodotin.

Price

2.3 The list price of belantamab mafodotin is £5,707.83 per 100‑mg vial (excluding VAT; BNF online, accessed April 2023).

2.4 The company has a commercial arrangement, which would have applied if belantamab mafodotin had been recommended.